3-deazaneplanocin has been researched along with azacitidine in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, MT; Cheyette, BN; Jiang, X; Kivimäe, S; Lee, PL; Li, J; Liu, ET; Stanton, LW; Tan, J; Yang, X; Yu, Q; Zhuang, L | 1 |
| Abe, M; Cortez, CC; Jones, PA; Kelly, TK; Liang, G; Marquez, VE; Miranda, TB; Yoo, CB | 1 |
| Chan, E; Marquez, VE; Sun, F; Wu, Z; Yang, X; Yu, Q | 1 |
| Borchardt, C; Clemens, D; Dirksen, U; Frühwald, MC; Kool, M; Unland, R | 1 |
| Han, L; Jiang, K; Kang, C; Liu, X; Ning, X; Shi, Z; Zhang, A; Zhang, Q | 1 |
| Clemens, D; Dirksen, U; Hotfilder, M; Klco-Brosius, S; Pettke, A; Potratz, J; Schaefer, C | 1 |
| Brand, OJ; Jenkins, G; Knox, AJ; Pang, L; Pasini, A | 1 |
| Dvořák Tomaštíková, E; Ercan, U; Finke, A; Krečmerová, M; Niezgodzki, I; Nowicka, A; Otmar, M; Pecinka, A; Poppenberger, B; Procházková, K; Rozhon, W; Schubert, I; Tokarz, B; Zwyrtková, J | 1 |
8 other study(ies) available for 3-deazaneplanocin and azacitidine
| Article | Year |
|---|---|
DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications.
Topics: Adaptor Proteins, Signal Transducing; Adenosine; Adenosylhomocysteinase; Apoptosis; Azacitidine; beta Catenin; Colorectal Neoplasms; Decitabine; Dishevelled Proteins; DNA Methylation; DNA Modification Methylases; Down-Regulation; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HCT116 Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Oligonucleotide Array Sequence Analysis; Phosphoproteins; Promoter Regions, Genetic; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transfection; Wnt Proteins | 2008 |
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.
Topics: Adenosine; Azacitidine; Blotting, Western; Cell Line; Cell Line, Tumor; Decitabine; DNA Methylation; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histones; Humans; Keratin-7; Methylation; Molecular Structure; Oligonucleotide Array Sequence Analysis; Polycomb Repressive Complex 2; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors | 2009 |
Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.
Topics: Adenosine; Antigens, Neoplasm; Azacitidine; Breast Neoplasms; Cell Line; Cell Line, Tumor; Chromatin Immunoprecipitation; Cluster Analysis; CpG Islands; Decitabine; DNA Methylation; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Immunoblotting; Methylation; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Polycomb Repressive Complex 2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription Factors | 2009 |
Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; Doxorubicin; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Polycomb Repressive Complex 2; Rhabdoid Tumor; Vorinostat | 2015 |
DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression.
Topics: Adenosine; Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Decitabine; Disease Progression; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioblastoma; Histones; Humans; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Polycomb Repressive Complex 2; Stomach Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell lines.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Osteosarcoma; Vorinostat | 2016 |
Suberanilohydroxamic acid prevents TGF-β1-induced COX-2 repression in human lung fibroblasts post-transcriptionally by TIA-1 downregulation.
Topics: Adenosine; Azacitidine; Cell Line; Cyclooxygenase 1; Cyclooxygenase 2; Decitabine; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Fibroblasts; Gene Expression Regulation; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung; Promoter Regions, Genetic; T-Cell Intracellular Antigen-1; Transforming Growth Factor beta1; Vorinostat | 2018 |
Comparative analysis of epigenetic inhibitors reveals different degrees of interference with transcriptional gene silencing and induction of DNA damage.
Topics: Adenosine; Arabidopsis; Azacitidine; Chromosome Aberrations; Cytidine; Decitabine; DNA Damage; DNA Methylation; DNA Repair; Epigenesis, Genetic; Gene Silencing; Heterochromatin; RNA Interference; Tandem Repeat Sequences | 2020 |